Search Site

Zilico Limited

Zilico News

Keep up to date with the latest news and press releases from Zilico.

  • 41 to 50 of 70
  • 1
  • 2
  • 3
  • 7
  • ZedScan expands international registration portfolio

    Oct '14 29

    Zilico Ltd’s cervical cancer diagnostic system ZedScan™ has been approved for use in Canada and Israel. ZedScan has been awarded a class II medical device licence by Health Canada. The Health Canada licence means that the system, which includes Zilico’s patented Electrical Impedance Spectroscopy technology, has been approved for clinical use as an adjunct to colposcopy in Canada. ZedScan has also now had its registration approved in Israel with AMAR, the Israeli Ministry of Health’s medical device regulation unit.
    more details ]
  • Proof of concept study published in International Journal of Nanomedicine

    Oct '14 24

    A study into the use of Zilico’s electrical impedance spectroscopy (EIS) platform technology to detect malignant and potentially malignant oral lesions has been published in the International Journal of Nanomedicine.
    more details ]
  • Sheffield to lead way for cervical cancer diagnosis

    Oct '14 20

    Patients at Sheffield Teaching Hospitals are to benefit from the introduction of a pioneering new system that improves the detection of pre-cancerous abnormalities of the cervix.
    more details ]
  • DP Medical secures deal with first NHS Trust for ZedScan™

    Oct '14 16

    DP Medical Ltd has secured a deal with Sheffield Teaching Hospitals NHS Foundation Trust (STHFT) to become the first NHS Trust in the country to adopt ZedScan™ as part of its cervical cancer care pathway.
    more details ]
  • Zilico named as finalists at Excellence in Supply Awards

    Oct '14 2

    Zilico Ltd has been named a finalist in the ‘Innovation – Clinical’ category at the North West Excellence in Supply Awards 2014.
    more details ]
  • ZedScan to be presented at Swedish Society of Obstetrics and Gynaecology meeting

    Sep '14 23

    Zilico Ltd has been invited to present its pioneering CE marked cervical cancer diagnostics system – ZedScan – at the Swedish Society of Obstetric and Gynaecology (SFOG) colposcopy meeting later this month.
    more details ]
  • Zilico receives backing for development of oral cancer diagnostic

    Jul '14 21

    Zilico Ltd has begun development work on a medical device which uses Electrical Impedance Spectroscopy (EIS) in the detection and diagnosis of oral cancer following funding from the Technology Strategy Board, the UK’s innovation agency.   The two awards are from the Biomedical Catalyst Feasibility and Smart Funds. The funds will help support an in-depth analysis of the UK market, deliver a product specification for an oral diagnostic device and a protocol for a multi-centre trial.
    more details ]
  • Zilico at IFCPC, 2014

    Jun '14 20

    Zilico Ltd recently exhibited at the 15th World Congress for Cervical Pathology and Colposcopy from the International Federation for Cervical Pathology and Colposcopy (IFCPC 2014) in London. Zilico presented its innovative diagnostic device, ZedScan, discussing its clinical and economic benefits to some of the world’s leading clinicians from the field of Colposcopy and Cervical Pathology with support from four of its distributors from Thailand, Israel, Ireland and UK.
    more details ]
  • ZedScan presented to international cervical pathology and colposcopy meeting

    May '14 20

    Zilico Ltd is set to present its innovative cervical cancer diagnostic system ZedScan™ to the foremost international meeting of cervical pathology and colposcopy clinicians for the first time since its CE Mark approval. ZedScan will be exhibited at the 15 th World Congress for Cervical Pathology and Colposcopy from the International Federation for Cervical Pathology and Colposcopy (IFCPC 2014) in London (26-30 May 2014). 
    more details ]
  • Zilico makes moves in the Australian Market

    Apr '14 15

    Zilico Ltd has made two major announcements which will see the company’s cervical cancer diagnostics product – ZedScan  I  – start being sold in to the Australian healthcare market. ZedScan  I  has obtained approval from Therapeutic Goods Administration (TGA) - the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia.
    more details ]